Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Brandes Small Cap Value Fund Brandes Investment Partners, L.P. | “Brandes re-entered Prestige Consumer Healthcare after share weakness created a value opportunity. Prestige owns market-leading brands such as Monistat, Dramamine, and Clear Eyes, focusing on acquiring underperforming brands and revitalizing them through marketing and innovation. The firm benefits from stable, defensive demand, niche markets with minimal private-label competition, and disciplined capital allocation toward share buybacks and M&A. BSD Analysis: Prestige's portfolio of durable OTC brands, low private-label risk, and recurring demand underpin steady FCF growth. With ~9x forward EV/EBITDA and shareholder-friendly capital deployment, the company remains a reliable compounder in the consumer healthcare space.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Heartland Value Plus Fund Andrew J. Fleming | “Prestige Consumer Healthcare (PBH) — the company behind familiar over-the-counter medical products such as Dramamine, Luden's cough drops, and Clear Eyes eye drops — was the biggest detractor to our Strategy's performance during the quarter. That's in part because PBH missed earnings forecasts and took down its full fiscal year EPS estimates due to supply chain issues related to its eye care business. Its core supplier was not able to ship enough products to meet demand for PBH's Clear Eyes business. The company took action to fix this supply chain issue, opting to acquire its eye care supplier for $100 million. This former supplier will now be 100% focused on producing for PBH after being brought in-house. We expect PBH's FY 2027 earnings to bounce back nicely as the core business is operating well and expect a rebound in PBH's profitable eye care business as customers re-stock inventory. At its price of $63 at the end of the third quarter, Prestige shares were trading at 13.8 times 2027 earnings. But we expect multiple expansion, as the company earnings are set to accelerate after addressing its supply chain issues. BSD Analysis: Near-term execution hiccups in eye care drove a guide-down, but vertical integration of the supplier should stabilize supply and margins. Core OTC portfolio is steady, suggesting earnings normalization into FY27. At a teens P/E on out-year EPS, multiple expansion is plausible as inventory restocking and in-house manufacturing flow through gross margin. Monitor integration risk and working capital cadence.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Ariel Appreciation Fund John W. Rogers | “Prestige Consumer Healthcare Inc. (PBH), a marketer and distributor of over-the-counter pharmaceutical products. The company has a strong track record of innovation and strategic acquisitions to address unmet consumer needs. Since an acquisition in 2017, PBH has focused on deleveraging the balance sheet through free cash flow. As the company continues to address customer-need through innovation, we expect earnings growth to drive multiple expansion. BSD Analysis: Prestige continues to showcase the resilience of its niche OTC brand portfolio, with consistent pricing power and stable category demand supporting robust cash generation. Management's playbook—acquire defensible brands, streamline costs, invest selectively—has produced dependable margins and steady deleveraging. The company's asset-light model and disciplined expense control make earnings less cyclical than most consumer peers, and recent execution has kept gross margins firm even in a volatile retail environment. Prestige doesn't chase big, flashy innovation; instead it leans into predictable, repeat-purchase categories where it can maintain leadership. The market still assigns a discount because the growth is steady rather than spectacular, but the reliability and cash conversion justify a higher valuation. As leverage declines and the M&A engine reopens, PBH remains a smooth, low-volatility compounder.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Ariel Focus Fund Ariel Investments, LLC | “New holding and distributor of over-the-counter pharmaceutical drugs and products, Prestige Consumer Healthcare Inc. (PBH), also declined following mixed earnings results and a downward revision to full-year guidance. Sales were impacted by limited inventory in the eye care segment, but the announced acquisition of Pillar5, a leading sterile ophthalmic manufacturer, is expected to strengthen supply over time. While ophthalmic recovery will be gradual, PBH reaffirmed its free cash flow outlook, supporting continued share repurchases and strategic acquisitions. Outside of eye care, the core portfolio delivered as expected, including gross margin expansion. BSD Analysis: Prestige continues to execute a quiet but highly effective OTC brand strategy, focusing on niche, defensible categories with stable demand and strong cash conversion. The company's asset-light model and disciplined pricing have kept margins resilient despite inflation and retailer inventory shifts. Integration of prior acquisitions remains strong, and management maintains a credible track record of deleveraging while expanding free cash flow. Prestige lacks the excitement of high-growth consumer names, but its consistency, visibility, and predictable cash generation are exactly what make it attractive. The stock trades below intrinsic value given its clean fundamentals and low-volatility profile. PBH remains a steady cash-flow compounder that tends to outperform when investors start rewarding durability over flash.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
